Ovid Therapeutics Inc.
OVID
Positions held
Your positionsOVID isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $457.00M | Enterprise value | $352.49M | Trailing P/E | — | Forward P/E | -6.04 |
| PEG | — | Price / book | 2.06 | Beta | 0.23 | Dividend yield | 0.00% |
| Revenue growth | -88.3% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -21.0% |
| Profit margin | 0.0% | ROE | -26.0% | ROA | -23.5% | Debt / equity | 0.06 |
| Current ratio | 12.39 | Free cash flow | -$33.12M | Analyst recommendation | strong_buy | Mean target | $6.02 |
| 52w high | $3.11 | 52w low | $1.18 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | $0.0M | $0.7M | $0.1M | $6.3M | — |
| Op margin | -2141.6% | — | -1712.1% | -9487.1% | -80.9% | — |
| Net income | -$15.0M | -$17.0M | $9.7M | -$12.2M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$15.7M | -$17.8M | -$12.3M | -$12.5M | -$5.1M | — |
- Operating margin compressed to -2141.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.3M | $0.6M | $0.4M | $1.5M | — |
| Op margin | -585.2% | -10933.7% | -15122.7% | -3696.4% | — |
| Net income | -$17.4M | -$26.4M | -$52.3M | -$54.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$42.4M | -$61.9M | -$59.3M | -$55.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
2026-10-06 · Guggenheim Initiates Ovid Therapeutics at Buy
2026-09-12 · Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
2026-09-03 · Ovid Therapeutics to Participate in Upcoming Investor Conferences
2026-08-18 · What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
2026-08-13 · Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-08-06 · Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-08-06 · Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-05 · Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
2026-08-03 · Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating
2026-07-14 · Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
Price (daily)
Full chart · RSI · MACD · patterns